Progress your MS Agent Program with our Well-Characterized Preclinical Models
Utilize preclinical models of experimental autoimmune encephalomyelitis (EAE) to evaluate agent efficacy in a clinically and pathologically relevant setting.
- Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (MOG-EAE) model
- Proteolipid protein-induced experimental autoimmune encephalomyelitis (PLP-EAE) relapsing-remitting model coming soon
MOG-EAE Model
Mice are immunized with MOG35-55 myelin-associated peptide in complete Freunds adjuvant to trigger immune response, then treated with pertussis toxin to promote increased transport of leukocytes across the blood-brain barrier. Disease onset occurs after Day 10.
Major Endpoints
- Weight loss
- Disease paralysis score
- Cytokine levels
- FACS analysis of immune cell populations
- Histopathology assessment of brain and spinal cord
Figure 1: MOG-EAE Model Validation with FTY-720 (Fingolimod)
Figure 2: MOG-EAE Mouse Model Representative Spinal Cord Histopathology
